...
首页> 外文期刊>Journal of Human Reproductive Sciences >Combined Use of Autologous Bone Marrow-derived Stem Cells and Platelet-rich Plasma for Ovarian Rejuvenation in Poor Responders
【24h】

Combined Use of Autologous Bone Marrow-derived Stem Cells and Platelet-rich Plasma for Ovarian Rejuvenation in Poor Responders

机译:联合使用自体骨髓衍生的干细胞和富含血小板血浆的卵巢恢复剂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: The management of poor responders is still a challenge in modern-assisted reproductive technology. Several researches are showing encouraging results with autologous bone marrow-derived stem cells (ABMDSCs) and platelet-rich plasma (PRP) individually. Hence, we decided to study the synergistic effect of ABMDSCs with PRP. Aims and Objective: The aim of the study was to assess the safety and efficacy of intraovarian instillation of ABMDSCs combined with PRP in poor responders. Design: This was an interventional pilot study. Study Period: January 2017 to January 2019. Materials and Methods: We designed a pilot study using Patient-oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) Group 3 and 4 poor responder patients ( n = 20). The study group underwent laparoscopic/transvaginal intraovarian instillation of ABMDSCs combined with PRP and the outcome was analyzed – primary outcome – antral follicular count (AFC) and mature MII oocytes and secondary outcome – Anti-Mullerian hormone (AMH) levels and number of Grade A and B embryos frozen on day 3. The Wilcoxon signed-rank test and Pearson correlation were used for the statistical analysis and P 0.05 was considered statistically significant. Results: After 6 weeks of intraovarian instillation ABMDSCs mixed with PRP, patients were reassessed for AFC and AMH and their response to subsequent controlled ovarian stimulation (COS) cycle was observed. Statistically significant improvement was seen in AFC, MII oocytes, and Grade A and Grade B embryos. AMH was also increased in some patients, but the result was not statistically significant. Conclusion: Our results suggest that intraovarian instillation of ABMDSCs combined with PRP is safe and it optimized the recruitment of existing dormant primordial follicles to improve oocyte yield and hence the number and quality of embryos after COS in POSEIDON Group 3 and 4 poor responders.
机译:背景:穷人的响应者管理仍然是现代辅助生殖技术的挑战。几项研究显示令人鼓舞的结果与自体骨髓衍生的干细胞(ABMDSCS)和富含血小板的血浆(PRP)单独进行。因此,我们决定研究ABMDSC与PRP的协同效应。目的和客观:该研究的目的是评估ABMDSC的中外管道滴注的安全性和有效性与贫困响应者的PRP联合。设计:这是一个介入的试点研究。研究期限:2017年1月至2019年1月。材料和方法:我们设计了使用患者导向的策略设计了一种患者卵母细胞数(Poseidon)3组和4名可怜的响应者患者(n = 20)的试验研究。该研究组接受了腹腔镜/经阴道术中滴注的ABMDSCS与PRP和结果进行了分析 - 主要结果 - 嗜睡卵泡计数(AFC)和成熟的MII卵母细胞和次级结果 - 抗Mullerian激素(AMH)水平和级数和B胚胎在第3天冷冻。威尔科克氏签名级别测试和Pearson相关用于统计分析,P <0.05被认为是统计学意义。结果:6周后宫内滴注ABMDSC与PRP混合后,针对AFC和AMH重新评估患者,并观察到其对随后受控卵巢刺激(COS)循环的反应。在AFC,MII卵母细胞和A级和B级胚胎中看到统计学上显着的改进。 AMH也在一些患者中增加,但结果没有统计学意义。结论:我们的研究结果表明,ABMDSC的术中滴注与PRP相结合是安全的,它优化了现有休眠原始卵泡的募集,提高卵母细胞产量,并因此在Poseidon组3和4个贫困响应者中的胚胎数量和质量。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号